World Library  
Flag as Inappropriate
Email this Article

Samarium (153Sm) lexidronam

Article Id: WHEBN0003383220
Reproduction Date:

Title: Samarium (153Sm) lexidronam  
Author: World Heritage Encyclopedia
Language: English
Subject: Samarium-153, Samarium, Yttrium-90, Radiation therapy, Samarium compounds
Publisher: World Heritage Encyclopedia

Samarium (153Sm) lexidronam

Samarium (153Sm) lexidronam
Systematic (IUPAC) name
Pentasodium samarium (153Sm) N,N,N‍ '​,N‍ '​-tetrakis(phosphonatomethyl)ethane-1,2-diamine
Clinical data
  • US: D (Evidence of risk)
Legal status
  • (Prescription only)
Routes of
Pharmacokinetic data
Bioavailability N/A
ATC code V10
PubChem CID:
Chemical data
Formula C6H12N2Na5O12P4153Sm
Molecular mass 695.93 g/mol

Samarium (153Sm) lexidronam (chemical name Samarium-153-ethylene diamine tetramethylene phosphonate, abbreviated Samarium-153 EDTMP, trade name Quadramet) is a chelated complex of a radioisotope of the element samarium with EDTMP. It is used to treat pain when cancer has spread to the bone.[1][2]

It is injected into a vein and distributed throughout the body, where it is preferentially absorbed in areas where cancer has invaded the bone. The radioisotope 153Sm, with a half-life of 46.3 hours, decays by emitting beta particles (electrons), which kill the nearby cells. Pain begins to improve in the first week for most people and the effects can last several months. It is commonly used in lung cancer, prostate cancer, breast cancer, and osteosarcoma.

Side effects

Side effects[3] include the following:

  • Black, tarry stools
  • Blood in urine/stool
  • Cough, hoarseness
  • Fever/chills
  • Lower back/side pain
  • Painful or difficult urination
  • Pinpoint red spots on skin
  • Irregular heartbeat
  • Nausea, vomiting

Supply and administration

Quadramet is supplied as a frozen solution for intravenous use with an activity of 50±5 mCi/mL.[4] Due to the short half-life of the radioisotope, the drug expires 56 hours after the noted calibration time.[4] Currently supported by Lantheus Medical Imaging.


  1. ^ Anderson P (August 2006). "Samarium for osteoblastic bone metastases and osteosarcoma". Expert Opin Pharmacother 7 (11): 1475–86.  
  2. ^ Finlay IG, Mason MD, Shelley M (June 2005). "Radioisotopes for the palliation of metastatic bone cancer: a systematic review". Lancet Oncol. 6 (6): 392–400.  
  3. ^ [3]"Quadramet Side Effects in Detail."
  4. ^ a b [4]"Quadramet Official FDA Information, side effects, and uses.", 2009.
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Hawaii eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.